Ono Pharmaceutical Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gyo Sagara
- Full Time Employees
- 3,853
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 8-2, Kyutaromachi 1-chome Osaka Japan 541-8564
- IPO Date
- Oct 2, 2012
- Website
- ono-pharma.com
- Similar Companies
- Business
- Ono Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company primarily engaged in the production, purchase, and sale of prescription and over-the-counter pharmaceuticals and diagnostic reagents. Founded in 1717 and headquartered in Chuo-ku, Osaka, Japan, the company offers a broad portfolio of products including oral drugs, injectable medicines, and patch formulations. Core products cover oncology therapies such as the anti-cancer drugs Velexbru, Braftovi, and Mektovi; treatments for catecholamine excess secretion like Demser; and a variety of prescription medicines targeting multiple therapeutic areas. Ono Pharmaceutical focuses heavily on research and development to innovate and deliver new drugs globally. In recent years, Ono Pharmaceutical has made significant strategic expansions, including the acquisition of US-based Deciphera Pharmaceuticals in April 2024 for approximately $2.4 billion, enhancing its oncology portfolio with Deciphera’s kinase inhibitor QINLOCK® (ripretinib), approved in over 40 countries for gastrointestinal stromal tumors. The acquisition strengthens Ono’s presence in the United States and Europe and accelerates its kinase drug discovery research. Additionally, the company has entered a co-development and marketing collaboration with Seikagaku for Gel-One, a treatment for osteoarthritis, and launched new clinical trials and therapies including povetacicept, a breakthrough therapy for kidney diseases. Ono also opened a new office in Zug, Switzerland in late 2025 to support growth in Europe and partner markets. The company continues active collaborations with biotech firms and research institutions to advance drug discovery, especially in oncology, immunology, neurology, and specialty medicines. Ono operates globally, with significant focus on Japan, the United States, and European markets. Its product pipeline includes small molecule drugs, monoclonal antibodies, synthetic peptides, and bispecific antibodies, with several drugs recently receiving FDA approvals. Subsidiaries include Deciphera Pharmaceuticals, functioning as a fully owned oncology-focused entity. Ono Pharmaceutical’s strategic direction emphasizes innovative cancer therapeutics, immunotherapies, and specialty medicines, maintaining its long-standing commitment to fighting disease and pain while expanding its global footprint through acquisitions, partnerships, and new product launches.
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
Ono Pharmaceutical Co., Ltd. (OPHLY) Presents at 44th Annual J.P.
Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 FY2025 Earnings Call Transcript
Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 2024 Earnings Call Transcript
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
ONO to buy Deciphera Pharmaceuticals at a huge premium
ONO to buy Deciphera Pharmaceuticals at a huge premium
Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billion
Japan's ONO Pharmaceutical to buy Deciphera for $2.4 billion
Ono Pharmaceutical Co. (OPHLF) Upgraded to Buy: Here's Why